Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 2/20 | 0.32 |
| ▸ | KCNT1 | Q5JUK3 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027677 | 0.89 | AHCY (0.40) | AHCYTP53MAPT | |
| SCHEMBL11975279 | 0.87 | AHCY (0.43) | AHCYHDAC4KCNT1GPR119NAMPT | |
| Hydrochloric Acid SCHEMBL11895746 | 0.86 | AHCY (0.44) | AHCYHDAC4KCNT1GPR119NAMPT | |
| SCHEMBL1196620 | 0.86 | HDAC4 (0.34) | HDAC4NPY2RKCNT1GPR119TP53 | |
| SCHEMBL1198040 | 0.82 | AHCY (0.42) | AHCYGPR119NAMPTTP53MAPT | |
| SCHEMBL11974831 | 0.82 | AHCY (0.43) | AHCYHDAC4KCNT1NAMPT | |
| SCHEMBL11903758 | 0.81 | AHCY (0.45) | AHCYNAMPTPARP1 | |
| Hydrochloric Acid SCHEMBL11903816 | 0.81 | AHCY (0.44) | AHCYHDAC4KCNT1NAMPT | |
| SCHEMBL11975774 | 0.80 | AHCY (0.50) | AHCYHDAC4NPY2RNAMPT | |
| SCHEMBL1026274 | 0.80 | HDAC4 (0.35) | AHCYHDAC4NPY2RKCNT1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | AHCY 4108/4885HDAC4 587/4885NPY2R 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.